FIELD: medicine, pharmaceutics.
SUBSTANCE: invention concerns biochemistry and medicine area. What is presented is a visualisation agent representing a conjugate of structure I as described in the patent claim. The visualisation agent refers to marked cMet-binding peptides. These peptides include a mark with an optical reporter group applicable for visualisation in vivo with the use of light within the range of wave length in the spectrum of 600-1200 nm. There are also presented a pharmaceutical composition for optical visualisation, containing the visualisation agent, a kit for preparing it and a method for optical visualization of a mammalian body in vivo. What is also presented is a method for managing the patients suffering colorectal cancer, involving the stage of optical visualisation in vivo.
EFFECT: presented visualisation agent possess higher cMet-binding affinity and selective cell targeting in vivo.
28 cl, 2 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION FOR OPTICAL VISUALIZATION, METHOD OF ITS PRODUCTION AND USE | 2019 |
|
RU2802481C2 |
| PEPTIDE COMPOSITION OF RADIOACTIVE INDICATORS | 2011 |
|
RU2594167C2 |
| OPTICAL VISUALISATION AGENTS | 2008 |
|
RU2484111C9 |
| DRUG CONJUGATES FROM MONOCLONAL CMET BINDING AGENTS AND THEIR USE | 2019 |
|
RU2813828C2 |
| COMPLEX CONTAINING Fab FRAGMENT OF ANTI-HUMAN MUC1 ANTIBODY, PEPTIDE LINKER AND/OR LIGAND | 2019 |
|
RU2814073C2 |
| PEPTIDE ANTAGONISTS OF CALCITONIN CGRP FAMILY OF PEPTIDE HORMONES AND THEIR USE | 2017 |
|
RU2742826C2 |
| CONJUGATES OF CMET ANTIBODY AND DRUG AND METHODS OF USING | 2017 |
|
RU2740996C2 |
| MONOCLONAL BINDING AGENTS, THEIR DRUG CONJUGATES AND THEIR APPLICATIONS | 2017 |
|
RU2744914C2 |
| GIP AGONIST COMPOUNDS AND METHODS | 2015 |
|
RU2716985C2 |
| PEPTIDE ANTAGONISTS OF PEPTIDE HORMONES FROM THE CALCITONIN GROUP (CALCITONIN GENE-RELATED PEPTIDES (CGRP)) AND THEIR APPLICATION | 2013 |
|
RU2624016C2 |
